发明名称 |
USE OF MTKI 1 FOR TREATING OR PREVENTING BONE CANCER |
摘要 |
The present invention is concerned with the finding that the macrocyclic quinazoline derivative 4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacyclo-pentadecine, 17-bromo-8,9,10,11,12,13, 14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication WO2004/105765, is useful in the manufacture of a medicament for the treatment or prevention of bone cancers and methods for killing bone cancer cells, including osteosarcomas, chondrosarcomas, myeloma bone disease and osteolytic bone metastases from other primary sites. It accordingly provides methods for treating, preventing, delaying or mitigating bone cancer, or for preventing and treating of bone loss associated with cancer metastases. |
申请公布号 |
WO2008049904(A2) |
申请公布日期 |
2008.05.02 |
申请号 |
WO2007EP61501 |
申请日期 |
2007.10.25 |
申请人 |
JANSSEN PHARMACEUTICA NV;PERERA, TIMOTHY, PIETRO, SUREN;JANICOT, MICHEL, MARIE, FRANCOIS;MEERT, THEO, FRANS;FREYNE, EDDY, JEAN, EDGARD |
发明人 |
PERERA, TIMOTHY, PIETRO, SUREN;JANICOT, MICHEL, MARIE, FRANCOIS;MEERT, THEO, FRANS;FREYNE, EDDY, JEAN, EDGARD |
分类号 |
A61K31/529;A61P35/00;A61P35/04 |
主分类号 |
A61K31/529 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|